IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options

Feb. 20, 2020 13:49 UTC

 

 
 

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE: IQV), a leader in human data science, today announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools help sites in Avacare’s network match patients to clinical trials faster and more effectively.

“We believe combining clinical research and patient care produces better patient outcomes, reduces cost of care, and advances research that will benefit patients,” said Cynthia Verst, president, Design and Delivery Innovation, Research & Development Solutions at IQVIA. “This is another example of IQVIA’s commitment to human data science, where our Avacare network enables practices to efficiently match trial participants to clinical trials, advancing medical innovation.”

Previously known as Qcare, Avacare has now expanded to include sites in the U.S. and India, with coverage across 19 therapeutic areas. Through existing physician relationships connected to approximately 6.5 million patients globally, Avacare provides innovative treatment options that drive healthcare forward.

Avacare uses innovative clinical technology with advanced analytics to deliver artificial intelligence-powered patient referrals and data-driven enrollment trends. By utilizing proprietary algorithms and privacy-protected health records across sites, Avacare precisely identifies the best patients to opt-in for each trial and supports the investigators in engaging patients for those trials.

To learn more about IQVIA’s Avacare Clinical Research Network, visit www.avacare.com.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

Contacts

Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732

Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144

 
 

Source: IQVIA

Back to news